The good news: Treatments and vaccines are coming that really could turn the tide in 2020
https://www.dailykos.com/stories/2020/5/2/1942082/-The-good-news-Treatments-and-vaccines-are-coming-that-really-could-turn-the-tide-in-2020
Behind remdesivir is another antiviral called leronlimab. The developer of the drug, CytoDyn, has reported ‘impressive results’ in a small trial of COVID-19 patients. Leronlamab is interesting for two big reasons. One, it attacks the mechanism through which viruses are able to reproduce themselves in human cells. Second, it can supposedly block the overwhelming immune response known as a “cytokine storm” that were thought to be responsible for most deaths during the 1918 flu epidemic and are known to be involved in some COVID-19 deaths. Being able to both fight the virus directly, and fight a potential cytokine storm is a big deal.
However, there are reasons Anthony Fauci isn’t yet standing up to make leronamib standard treatment. First, the results CytoDyn is promoting came from small-scale phase 1/2 trials in which only a total of around 25 patients have actually received the drug. Second, though the fact that leronamib was developed as an HIV treatment (and is being studied for use against metastatic breast cancer) rather than for Ebola may make it seem like it might be available in greater quantities, but in fact it is still in clinical trials for use against HIV. Finally, there have so far been few published results from the initial trials that allows objective review of the results.
In any case, the results from early trials of leronamib have been exciting enough that researchers have already jumped into a number of larger trials. And, in part because clinical trials for leronamib with HIV have shown limited side effects, it’s being used on patients with mild or moderate symptoms in addition to those with severe forms of COVID-19. In other words, loronamib might turn out to be a treatment that is given broadly to anyone showing symptoms, rather than just those on the border of critical conditions. Big emphasis on might.
But there do seem to be indications that general antivirals, like remdesivir and leronamib, can have an impact on COVID-19. And that’s a very good thing. The way in which viruses work, by hijacking the mechanisms of the cells they invade, means that fighting them can be extremely difficult. There is a reason there are many, many more antibiotics and antivirals.